Abbvie Inc., of North Chicago, reported results from PIONEER II, a pivotal phase III study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate to severe hidradenitis suppurative, specifically the number of abscesses and inflammatory nodules.